Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood (2023) 142 (19): 1647–1657.

https://doi.org/10.1182/blood.2023020649

Published: 2023

Includes: Supplemental data

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

Tareq Abuasab, Srdan Verstovsek, Gautam Borthakur, Rashmi Kanagal-Shamanna, Keyur Patel, Koichi Takahashi, Lucia Masarova, Prithviraj Bose, John Villarreal, Sherry A. Pierce, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Nicholas Short, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 8954–8956.

https://doi.org/10.1182/blood-2022-165455

Published: 2022

Journal Articles

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Blood (2022) 140 (Supplement 1): 6306–6308.

https://doi.org/10.1182/blood-2022-164494

Published: 2022

Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Blood (2022) 140 (Supplement 1): 543–545.

https://doi.org/10.1182/blood-2022-156955

Published: 2022

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Blood (2022) 140 (Supplement 1): 234–237.

https://doi.org/10.1182/blood-2022-170850

Published: 2022

Journal Articles

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

Blood (2021) 138 (Supplement 1): 798.

https://doi.org/10.1182/blood-2021-154143

Published: 2021

Journal Articles

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Curtis Lachowiez, Courtney D. DiNardo, Kiyomi Morita, Ken Furudate, Feng Wang, Tomoyuki Tanaka, Sa A Wang, Tapan M. Kadia, Naval Daver, Nicholas J. Short, Joseph D. Khoury, Keyur Patel, L. Jeffrey Medeiros, Marina Konopleva, Farhad Ravandi, Koichi Takahashi, Sanam Loghavi

Blood (2021) 138 (Supplement 1): 607.

https://doi.org/10.1182/blood-2021-148971

Published: 2021

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Blood (2021) 138 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2021-154454

Published: 2021

Journal Articles

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

Blood (2021) 138 (Supplement 1): 370.

https://doi.org/10.1182/blood-2021-153426

Published: 2021

Journal Articles

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 54–56.

https://doi.org/10.1182/blood-2020-137176

Published: 2020

Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141411

Published: 2020

Journal Articles

Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Elias Jabbour, MD, Yue Wei, PhD, Faezeh Darbaniyan, PhD, Mark Routbort, MD PhD, Sherry A. Pierce, BSN, BA, Kelly A. Soltysiak, PhD, Keyur Patel, MD PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141446

Published: 2020

Journal Articles

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Blood (2020) 136 (Supplement 1): 26–29.

https://doi.org/10.1182/blood-2020-137212

Published: 2020

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-142014

Published: 2020

Journal Articles

Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression

Siba El Elhussein, MD, L. Jeffrey Medeiros, MD, Kirill A. Lyapichev, MD, Stephen K. Gruschkus, PhD MPH, Peng Wei, PhD, Ellen Schlette, MD, Warren Fiskus, BSc,PhD, Rashmi Kanagal-Shamanna, MD, Sanam Loghavi, MD, Hong Yang, MD PhD, Shaoying Li, MD, Jie Xu, MD, Zhenya Tang, MD PhD, Beenu Thakral, MD, Nitin Jain, MD, William G. Wierda, MD PhD, Keyur Patel, MD PhD, Kapil N. Bhalla, MD, Joseph D. Khoury, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143122

Published: 2020

Journal Articles

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Rashmi Kanagal-Shamanna, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Nicholas J. Short, MD, C. Cameron Yin, MD PhD, Keyur Patel, MD PhD, Sanam Loghavi, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Susan M. O'Brien, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-142012

Published: 2020

Journal Articles

Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136978

Published: 2020

Journal Articles

Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53 -Mutated Acute Myeloid Leukemia

Nicholas J. Short, MD, Guillermo Montalban-Bravo, MD, Hyunsoo Hwang, Jing Ning, PhD, Miguel Franquiz, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Courtney D. Dinardo, MDMSc, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Koichi Takahashi, MD PhD, Marina Konopleva, MD PhD, Naval Daver, MD, Elias Jabbour, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Michael Andreeff, MD PhD, Tapan M. Kadia, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-134312

Published: 2020

Journal Articles

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Keyur Patel, MD PhD, Steven M. Kornblau, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Marina Konopleva, MD PhD, Nitin Jain, MD, Partow Kebriaei, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Jairo A. Matthews, Munazza Noor, Rebecca Garris, MSc, Farhad Ravandi, MBBS, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-141971

Published: 2020

NARROW

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma

Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53 -Mutated Acute Myeloid Leukemia

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only